Skip to content

Geron GERN Debt-to-assets

Debt-to-assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Incyte logo
IncyteINCY
0.0×
Immunome logo
ImmunomeIMNM
0.0×
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
0.7×+0.2×
Arcus Biosciences logo
Arcus BiosciencesRCUS
0.1×+0.1×
Celcuity logo
CelcuityCELC
0.3×-0.1×

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-8.6%
Enterprise value$973.78M-6.2%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Calculated from Geron’s reported figures.

Based on the most recent quarter.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's debt-to-assets?
Geron (GERN) reported debt-to-assets of 0.3× in Q1 2026.
How has Geron's debt-to-assets changed year-over-year?
Geron's debt-to-assets increased by 15.9% year-over-year, from 0.2× to 0.3×.
What is the long-term trend for Geron's debt-to-assets?
Over 5 years (2020 to 2025), Geron's debt-to-assets has grown at a 14.3% compound annual growth rate (CAGR), from 0.1× to 0.2×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.